search
Back to results

Fosfomycin Versus Standard of Care in Children With Antibiotic-resistant Urinary Tract Infections (FosUTI)

Primary Purpose

Urinary Tract Infections

Status
Not yet recruiting
Phase
Phase 3
Locations
Australia
Study Type
Interventional
Intervention
Fosfomycin 3000 MG [Monurol]
Standard of care
Sponsored by
University of Sydney
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Urinary Tract Infections

Eligibility Criteria

1 Year - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Children aged ≥1 to <18 years with: Symptoms suggestive of a clinical diagnosis of a UTI (as per the treating clinician); AND Microbiological confirmation: Defined as a urine culture revealing pure growth of a single bacterial uropathogen [≥106 CFU/L, or ≥103 CFU/mL] together with ≥10 white blood cells [WBCs] per high power field in centrifuged urine on microscopy, or ≥10 WBCs/mm3 in uncentrifuged urine]; AND The bacterial uropathogen is one of: Escherichia coli, Proteus spp., Klebsiella spp., Enterobacter spp., Serratia spp., or Citrobacter spp., AND The uropathogen has evidence of resistance to all oral penicillins and cephalosporins AND The patient has not yet received ≥48 hours of antibiotics effective against the urinary pathogen prior to enrolment. Exclusion Criteria: Evidence of bacteraemia due to the same uropathogen within the same clinical illness; OR Evidence of infection at a secondary site (such as CNS infection or endocarditis); OR Children with features suggestive of sepsis (defined as requiring inotropic support, or >20ml/kg fluid bolus); OR Children who are unable to tolerate or absorb oral antibiotics; OR Creatinine clearance <40ml/minute; OR Known allergy to fosfomycin.

Sites / Locations

  • Sydney Childrens Hospital
  • Royal Childrens Hospital
  • Royal Perth Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Intervention arm

Standard of Care Arm

Arm Description

A single dose of oral fosfomycin trometamol (Monurol), dosed as: ≥ 1 to <12 years of age: 2 grams (of fosfomycin base) as a single dose Children ≥ 12 years and <18 years of age: 3 grams (of fosfomycin base) as a single dose For children who have persistent fevers at 48 hours, the dose of oral fosfomycin may be repeated every 48 hours, to a maximum of 3 doses. For a subset of 30 children aged 1-12 years (inclusive) at the primary recruitment sites (RCH, SCH and CHW) two blood samples will be taken after the first oral fosfomycin dose to determine plasma fosfomycin concentrations. The timing of these samples after the oral fosfomycin dose are as follows, with participants being randomly allocated to one of the two sampling groups: Sample 1 Sample 2 Group 1 (n=15) 20 minutes to 180 minutes post dose 4-12 hours post dose Group 2 (n=15) 120 to 240 minutes post dose 12 to 18 hours post dose

Management as per physician preference based on institutional prescribing practices and local antibiograms. For participants administered an oral antibiotic in the Standard of Care arm, a tolerability questionnaire will be administered at the time of the first dose.

Outcomes

Primary Outcome Measures

Treatment failure at 28 days after enrolment between patients treated with SOC versus PO fosfomycin.
Treatment failure will be defined as: Recurrent (clinical and microbiologically-confirmed) UTI within 28 days of enrolment, with the same uropathogen; or Decision to switch to an alternative antibiotic due to perceived treatment failure; or Isolation of the same pathogenic organism from a new sterile site within 28 days after enrolment; whereby microbiological confirmation might only include the evidence of pyuria (in the absence of epithelial cells) and may or may not include a positive urine culture.

Secondary Outcome Measures

Treatment arm comparison
To compare, between the two treatment arms, the proportion of children with: Treatment-related adverse effects and serious adverse effects; Severe complications attributable to their UTI (as judged by the clinician), including: Admission to intensive care; or The development of UTI complications (abscess, sepsis, meningitis); Persistent symptoms attributable to their urinary tract infection at 10 days after enrolment; Re-presentation with a UTI within 28 days of enrolment; The use of hospital resources in children receiving SOC versus oral fosfomycin; The tolerability of fosfomycin versus other oral antibiotics; and Quality of life indicators for children prescribed SOC versus oral fosfomycin.

Full Information

First Posted
January 23, 2023
Last Updated
February 5, 2023
Sponsor
University of Sydney
search

1. Study Identification

Unique Protocol Identification Number
NCT05709028
Brief Title
Fosfomycin Versus Standard of Care in Children With Antibiotic-resistant Urinary Tract Infections
Acronym
FosUTI
Official Title
Fosfomycin Versus Standard of Care in Children With Antibiotic-resistant Urinary Tract Infections
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
April 2023 (Anticipated)
Primary Completion Date
February 2026 (Anticipated)
Study Completion Date
February 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Sydney

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of this clinical trial is to determine, in children with multi-drug resistant urinary tract infections, whether oral fosfomycin is noninferior to standard of care antibiotics in achieving a cure without recurrence within 30 days of treatment. The The main questions the trial aims to answer are: Is oral fosfomycin inferior in efficacy to the current standard to care for multi-drug resistant UTIs in children as defined by the recurrence of a UTI within 30 days of completion of therapy? Is fosfomycin a safe and well-tolerated antibiotic in children? Participants aged ≥1 to <18 years of age with a clinical diagnosis of antibiotic-resistant urinary tract infections will be recruited and randomised after informed consent is obtained via computer generated randomisation into standard of care or intervention (treatment with oral fosfomycin) arms. For children randomised into the standard of care arm: Management will be as per physician preference based on institutional prescribing practices and local antibograms. For children randomised into the intervention arm: a single dose of oral fosfomycin trometamol will be prescribed (with dosage determined based on age). Both groups will complete a tolerability questionnaire and be subject to physical examination, pathology investigations and other clinical interventions tailored to their needs as per routine standard of care. Clinical observations and results of the investigation will be recorded on a case report form via an electronic database. A follow-up safety review will be performed 10 and 28 days after enrollment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Urinary Tract Infections

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Randomised controlled trial with an intervention arm and a control arm (standard-of care)
Masking
None (Open Label)
Masking Description
Open-label study. Statisticians will be blind to groups when analysing results
Allocation
Randomized
Enrollment
300 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention arm
Arm Type
Experimental
Arm Description
A single dose of oral fosfomycin trometamol (Monurol), dosed as: ≥ 1 to <12 years of age: 2 grams (of fosfomycin base) as a single dose Children ≥ 12 years and <18 years of age: 3 grams (of fosfomycin base) as a single dose For children who have persistent fevers at 48 hours, the dose of oral fosfomycin may be repeated every 48 hours, to a maximum of 3 doses. For a subset of 30 children aged 1-12 years (inclusive) at the primary recruitment sites (RCH, SCH and CHW) two blood samples will be taken after the first oral fosfomycin dose to determine plasma fosfomycin concentrations. The timing of these samples after the oral fosfomycin dose are as follows, with participants being randomly allocated to one of the two sampling groups: Sample 1 Sample 2 Group 1 (n=15) 20 minutes to 180 minutes post dose 4-12 hours post dose Group 2 (n=15) 120 to 240 minutes post dose 12 to 18 hours post dose
Arm Title
Standard of Care Arm
Arm Type
Active Comparator
Arm Description
Management as per physician preference based on institutional prescribing practices and local antibiograms. For participants administered an oral antibiotic in the Standard of Care arm, a tolerability questionnaire will be administered at the time of the first dose.
Intervention Type
Drug
Intervention Name(s)
Fosfomycin 3000 MG [Monurol]
Intervention Description
A single dose of oral fosfomycin trometamol, dosed as: ≥ 1 to <12 years of age: 2 grams (of fosfomycin base) as a single dose Children ≥ 12 years and <18 years of age: 3 grams (of fosfomycin base) as a single dose For children who have persistent fevers at 48 hours, the dose of oral fosfomycin may be repeated every 48 hours, to a maximum of 3 doses. Fosfomycin trometamol is a white crystalline powder which is very soluble in water. The granules are mixed with 90ml of cool water for the constitution to dissolve and will be administered soon after reconstitution. Each 30ml will contain 1g fosfomycin base. Children ≥ 1 to 11 years will be administered 60ml (=2g fosfomycin base) of dissolved solution and the remainder discarded. Children ≥12 and <18 years will be administered the entire 90ml dose ( = 3g fosfomycin base).
Intervention Type
Other
Intervention Name(s)
Standard of care
Intervention Description
Comparator arm where treatment is provided as per standard of care as per physicians preference
Primary Outcome Measure Information:
Title
Treatment failure at 28 days after enrolment between patients treated with SOC versus PO fosfomycin.
Description
Treatment failure will be defined as: Recurrent (clinical and microbiologically-confirmed) UTI within 28 days of enrolment, with the same uropathogen; or Decision to switch to an alternative antibiotic due to perceived treatment failure; or Isolation of the same pathogenic organism from a new sterile site within 28 days after enrolment; whereby microbiological confirmation might only include the evidence of pyuria (in the absence of epithelial cells) and may or may not include a positive urine culture.
Time Frame
28 days
Secondary Outcome Measure Information:
Title
Treatment arm comparison
Description
To compare, between the two treatment arms, the proportion of children with: Treatment-related adverse effects and serious adverse effects; Severe complications attributable to their UTI (as judged by the clinician), including: Admission to intensive care; or The development of UTI complications (abscess, sepsis, meningitis); Persistent symptoms attributable to their urinary tract infection at 10 days after enrolment; Re-presentation with a UTI within 28 days of enrolment; The use of hospital resources in children receiving SOC versus oral fosfomycin; The tolerability of fosfomycin versus other oral antibiotics; and Quality of life indicators for children prescribed SOC versus oral fosfomycin.
Time Frame
28 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Children aged ≥1 to <18 years with: Symptoms suggestive of a clinical diagnosis of a UTI (as per the treating clinician); AND Microbiological confirmation: Defined as a urine culture revealing pure growth of a single bacterial uropathogen [≥106 CFU/L, or ≥103 CFU/mL] together with ≥10 white blood cells [WBCs] per high power field in centrifuged urine on microscopy, or ≥10 WBCs/mm3 in uncentrifuged urine]; AND The bacterial uropathogen is one of: Escherichia coli, Proteus spp., Klebsiella spp., Enterobacter spp., Serratia spp., or Citrobacter spp., AND The uropathogen has evidence of resistance to all oral penicillins and cephalosporins AND The patient has not yet received ≥48 hours of antibiotics effective against the urinary pathogen prior to enrolment. Exclusion Criteria: Evidence of bacteraemia due to the same uropathogen within the same clinical illness; OR Evidence of infection at a secondary site (such as CNS infection or endocarditis); OR Children with features suggestive of sepsis (defined as requiring inotropic support, or >20ml/kg fluid bolus); OR Children who are unable to tolerate or absorb oral antibiotics; OR Creatinine clearance <40ml/minute; OR Known allergy to fosfomycin.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Michelle L Harrison
Phone
0411900359
Email
m.harrison@sydney.edu.au
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Phoebe Williams
Organizational Affiliation
University of Sydney
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sydney Childrens Hospital
City
Sydney
State/Province
New South Wales
ZIP/Postal Code
2031
Country
Australia
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Phoebe Williams
Phone
+61411445575
Email
phoebe.williams1@health.nsw.gov.au
First Name & Middle Initial & Last Name & Degree
Phoebe Williams
First Name & Middle Initial & Last Name & Degree
Robert Duguid
Facility Name
Royal Childrens Hospital
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3052
Country
Australia
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amanda Gwee
Phone
+61 3 9345 5522
Email
Amanda.Gwee@rch.org.au
First Name & Middle Initial & Last Name & Degree
Amanda Gwee
Facility Name
Royal Perth Hospital
City
Perth
State/Province
Western Australia
ZIP/Postal Code
6000
Country
Australia
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Daniel Yeoh
Phone
+614 2352 0575
Email
daniel.yeoh@health.wa.gov.au
First Name & Middle Initial & Last Name & Degree
Daneial Yeoh

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Efficacy and AEs/SAEs will be summarised and pooled. Deidentified individual data will be shared with the DSMB and ethics for SAEs only. Investigators have the protocols and the ICFs. SAP will be available for all investigators once authored. Reports and analytical code will be shared when approved by trial statisticians.

Learn more about this trial

Fosfomycin Versus Standard of Care in Children With Antibiotic-resistant Urinary Tract Infections

We'll reach out to this number within 24 hrs